Cited by 43Diabetes Treatment and ManagementDiabetes Management and ResearchGeriatric Care and Nursing Homes

A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: linagliptin-LTC trial

Open access
Umpierrez, Guillermo E., Cardona, Saumeth, Chachkhiani, David, Fayfman, Maya, Saiyed, Sahebi, Wang, Heqiong, Vellanki, Priyathama, Haw, J. Sonya +3 more·2018·Journal of the American Medical Directors Association

Abstract

Objectives Safe and easily implemented treatment regimens are needed for the management of patients with type 2 diabetes mellitus (T2DM) in long-term care (LTC) and skilled nursing facilities.Design This 6-month open-label randomized controlled trial compared the efficacy and safety of a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in LTC residents with T2DM.Settings Three LTC institutions affiliated with a community safety-net hospital, US Department of Veterans Affairs and Emory Healthcare System in Atlanta, Georgia.Participants A total of 140 residents with T2DM treated with oral antidiabetic agents or low-dose insulin (≤0.1 U/kg/d), with fasting or premeal blood glucose (BG) > 180 mg/dL and/or HbA1c >7.5%.Intervention Baseline antidiabetic therapy, except metformin, was discontinued on trial entry. Residents were treated with linagliptin 5 mg/d (n = 67) or glargine at a starting dose of 0.1 U/kg/d (n = 73). Both groups received supplemental rapid-acting insulin before meals for BG > 200 mg/dL.Measurements Primary outcome was mean difference in daily BG between groups. Main secondary endpoints included differences in frequency of hypoglycemia, glycosylated hemoglobin (HbA1c), complications, emergency department visits, and hospital transfers.Results Treatment with linagliptin resulted in no significant differences in mean daily BG (146 ± 34 mg/dL vs. 157 ± 36 mg/dL, P = .07) compared to glargine. Linagliptin treatment resulted in fewer mild hypoglycemic events <70 mg/dL (3% vs. 37%, P < .001), but there were no differences in BG < 54 mg/dL (P = .06) or <40 mg/dL (P = .05) compared to glargine. There were no significant between-group differences in HbA1c, length of stay, complications, emergency department visits, or hospitalizations.Conclusion Treatment with linagliptin resulted in noninferior glycemic control and in significantly lower risk of hypoglycemia compared to insulin glargine in long-term care and skilled nursing facility residents with type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jamda.2017.11.002

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Umpierrez, G. E., Cardona, S., Chachkhiani, D., Fayfman, M., Saiyed, S., Wang, H., Vellanki, P., Haw, J. S., Olson, D. E., Pasquel, F. J., & Johnson, T. M.
Affiliations
Emory University (US)
Corresponding author
Umpierrez, Guillermo E.
Venue
Journal of the American Medical Directors Association
Publisher
Elsevier BV
Published
2018-05
Volume
19
Issue
5
Pages
399-404.e3
ISSN
1525-8610 (ISSN-L)
OpenAlex
W2776839462
Cited by
43
References
40
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 8
FWCI
4.11
Type
journal article
Language
en
Update notices
erratum (2019-07-01)
Open access
Locations
  • Journal of the American Medical Directors Association (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR002378)
  • National Institute on Aging (U54AG062334)
  • National Institute of Allergy and Infectious Diseases (R38AI140299)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024)
  • National Center for Advancing Translational Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD085850)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Health Professions › General Health Professions › Geriatric Care and Nursing Homes
Keywords
linagliptin, DPP-4 inhibitors, basal insulin, glargine, type 2 diabetes, long-term care, skilled nursing facilities, glycemic control, hypoglycemia, HbA1c, rapid-acting insulin, non-inferiority, veterans, older adults, emergency department visits, hospitalization, length of hospital stay, cost-effectiveness
MeSH terms
Insulin Glargine, Linagliptin, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Residential Facilities, Skilled Nursing Facilities, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review